Explore Our Network

Astrapi Corporation is a leader in revolutionary communication methods, specifically through spiral-based modulation. One capability is the Astrapi Spectrum Analyzer which enables an extremely precise method to measure continuously varying signal power which includes brain waves. This innovative technology is set to transform the next generation of communications by enhancing spectral efficiency and providing new ways to combat channel impairments. Astrapi's technology supports performance advances across various communications networks, including cellular, satellite, and defense communications, among others. Important medical applications of the Astrapi Spectrum Analyzer may include: 1. brain disorder diagnostics and measurement; 2. tumor localization; 3. enhanced prosthetics; and 4. brain-computer interfaces. Astrapi is in the process of spinning out a medical company to focus specifically on the medical applications of its Spectrum Analyzer. We welcome investors and collaborators. Our business model is to license to companies already in the medical field.

Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is advancing to Phase 2 clinical trials.

Berkeley FIT is dedicated to fostering innovation through technology, specializing in AI, software engineering, and digital product design. The company partners with both industry leaders and startups to solve complex challenges, leveraging expertise in modern software development, cloud platforms, AI & machine learning, and user-centered UX/UI design. Their mission is to bridge the gap between current needs and future possibilities by delivering technology-driven solutions with real-world impact.

Celestial Therapeutics is a Johnson & Johnson Innovations-JLABS resident California-based biotechnology company focused on developing innovative therapies to treat, prevent, and cure infectious diseases, rare diseases, and cancers. The company leverages groundbreaking science to create dual-modal antivirals/anti-inflammatories, mRNA vaccines, and therapeutics. Founded in 2019, Celestial has rapidly built a diverse portfolio based on its innovative innate immunity platform technologies, aiming to address significant unmet medical needs worldwide.

Cellphire Therapeutics' vision is that no-one should die from controllable hemorrhage. In the US, hemorrhage remains a leading cause of preventable death for those under 45. For this reason, we need new products with improved hemostatic efficacy and ensure they are in the hands of clinicians when they are needed. The extremely short shelf-life – 7 days max – of platelets used as the standard of care Liquid Stored Platelets (LSP) gives rise to an inability to create an inventory buffer to address any increase in demand, particularly mass casualty events, military conflicts or significant hemorrhage situations such as post-partum hemorrhage and traumatic injury. This means: 1) Platelet rationing occurs across the system. 2) Nearly 400,000 platelet units a year expire before they can get to a patient in need. 3) Ten million Americans on anti-platelet or anticoagulant medications face greater risks when effective therapies aren’t available to clinicians, complicating surgery and trauma care.

ClotProtect Therapeutics Limited is a UK-based therapeutics spin-out from the University of Leeds, pioneering a first-in-class small molecule anti-fibrinolytic to address acute bleeding. The company is led by a team of world-leading scientific experts, clinical key opinion leaders, and experienced pharma industry professionals. Their mission is to transform the treatment of acute haemorrhage and traumatic bleeding, aiming to save lives with innovative, more effective therapies. ClotProtect is currently in preclinical development, working towards identifying a clinical drug candidate that offers superior efficacy and safety compared to current standards of care.

CMTx Biotech, Inc. is an emerging biopharmaceutical company working to develop and commercialize host-directed therapeutics for the treatment of inflammatory and infectious diseases, as well as threat-agnostic medical countermeasures against high-priority chemical, biological, radiological and nuclear (CBRN) threats to homeland security and national defense. Our lead drug candidate is a clinically-tested, highly-stable, orally-administered small molecule that has been shown to improve survival and prevent lung injury in a wide variety of animal models of sepsis, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) across several species, including mice, rats, hamsters, pigs and sheep. Having already secured approximately $4M in funding to-date, including $3.6M in NIH SBIR/STTR grants, we are actively seeking non-dilutive funding, private investment capital and/or an established strategic partner to help advance human clinical trials and FDA Animal Rule development, as well as to expand our product pipeline.

Cohesys is a clinical-stage company focused on innovating fracture repair solutions. Its product, BoneTape, is the first bone fixation device that does not require drilling into healthy bone. The company aims to disrupt the traditional surgical-repair industry that relies on invasive plates and screws.

CranioSense, Inc. is a clinical stage company focused on revolutionizing the measurement of intracranial pressure (ICP) with their innovative IPASS technology. This non-invasive solution aims to provide rapid and safe ICP assessments, addressing the critical need for better management of traumatic brain injury (TBI) and other conditions associated with elevated cranial pressure. By eliminating the need for invasive procedures, CranioSense is poised to significantly improve patient outcomes and healthcare practices.

DANE Health, Inc. created an Agentic Medical AI assistant, initially concentrating on neurology and triage to revolutionize care pathways. The company provides individuals and healthcare professionals with practical insights, tailored support, and professional reports, all while ensuring privacy and security. Our AI agent engages in lifelike conversations to tackle complex management or recovery challenges, while monitoring progress over time. DANE Health aims to supply clinicians with clear data to improve patient care and aid in better recovery.

FiteBac Technology/FiteBac Pharma's innovations stem from the work of numerous international academic research scientists. FiteBac Pharma K21 is the blockbuster antimicrobial small molecule designed to modulate biological, immunological, and metabolic systems for treating a wide range of infectious and inflammatory diseases. This patented drug substance has demonstrated the ability to safely eliminate bacterial, fungal, and viral infections, enhance innate immunity, induce mitophagy while improving mitochondrial and cellular metabolism, accelerate wound healing, and even promote the development of zebrafish and chickens, leading to increased adult mass. Rigorous research from Dr. Bhupesh Prusty's laboratory and Dr Christopher Rongo's laboratory is focused on various aspects of mitochondrial remodeling and reprograming, as well as mitochondrial-to-nuclear signaling with K21. FiteBac K21 uniquely targets the underlying disease state, given that most diseases involve microbial-associated inflammation and mitochondrial dysfunction.

Frontier Bio creates lab-grown human tissues to eliminate the organ transplant list and as an ethical alternative to animal studies. They're starting with blood vessels since they are the foundation for all tissues.

GreenLifeTech is dedicated to improving sustainability by extending the shelf life of fresh produce, thereby reducing food waste and promoting healthier living. In addition, the technology is applicable to preserving transfusion blood. Their initial innovative product, FreshDefend™, is a smart countertop system that can extend the life of fruits and vegetables by up to five times without the use of harmful chemicals. The company is committed to environmental sustainability, reducing agricultural waste, and supporting communities through charitable donations.

Gryphon Bio is a clinical stage company focused on developing novel blood tests for brain health, leveraging over 20 years of -omic research to identify brain-specific biomarkers in the blood. Their mission is to improve patient lives through innovative diagnostics for various central nervous system (CNS) diseases.

Healables is a wartime veteran-owned HealthTech and SportsTech startup focused on developing closed-loop AI-driven wearables and smart textiles designed to accelerate recovery, enhance performance and reduce inflammation. Healables aims to provide personalized solutions ranging from predictive analytics to wearable and digital therapeutics for the sports, civilian and military markets. Our product pipeline includes novel solutions for MSK, PTSD and diabetic neuropathy.

iXpressGenes is a biotechnology company dedicated to transforming trauma care through innovative, science-driven solutions. Their mission is to bridge the gap between mental and physical health by detecting and addressing trauma-induced conditions before symptoms emerge. Leveraging advanced RNA biomarker technology, iXpressGenes empowers healthcare providers to deliver proactive, data-driven care that prevents long-term suffering and improves patient outcomes. The company is committed to early detection, prevention, and the development of tools that legitimize the biological realities of trauma, ultimately redefining the future of trauma care.

KaloCyte, Inc. is a pre-clinical stage biotech company focused on developing ErythroMer™, a dried, bio-inspired artificial red blood cell that is shelf-stable without refrigeration. This innovative solution aims to address the critical need for blood substitutes in emergency situations where stored red blood cells are unavailable, undesirable, or in short supply. Founded by a team of experts in physiology, bioengineering, and trauma care, KaloCyte is supported by significant federal grants and investor funding, positioning it to advance to first-in-human trials.

Lactea Therapeutics, founded in 2021 in Frederick, MD, is dedicated to advancing naturally occurring, safe, broad-spectrum active molecules as a new class of antibiotic alternatives. Their mission is to reduce the risk of resistance, limit disruption of the microbiome, and decrease the transmission of harmful microbes by harnessing the power of innate immune system proteins. The company leverages patent-pending technology to develop products based on endemic proteins that have evolved to provide broad protection against infections, aiming to translate these natural defenses into pharmaceutical solutions.

Limax Biosciences is dedicated to revolutionizing tissue healing through innovative biomaterials inspired by the natural slime of slugs. Their hydrogels provide superior adhesion and healing capabilities, addressing unmet medical needs both inside and outside the body.

Lumen Bioscience is dedicated to unlocking the full potential of biologic drugs by transforming their development, cost, and accessibility. Utilizing patented technology, Lumen aims to develop biologic drugs faster, safer, and more effectively than traditional methods, addressing diseases that have been neglected by conventional drug-making tools.